Farydak approved for multiple myeloma

(HealthDay)—Farydak (panobinostat) has been approved by the U.S. Food and Drug Administration to treat multiple myeloma, a cancer of the blood.

Affecting mostly older adults, the disease causes blood plasma cells to multiply rapidly, overtaking other healthy blood cells from the . This can weaken the immune system and lead to bone and kidney problems, the FDA said in a news release.

Multiple myeloma is diagnosed in almost 22,000 Americans annually, killing about 10,700 each year, according to the U.S. National Cancer Institute.

Farydak inhibits enzymes called (HDACs), which could slow the overproduction of among people with multiple myeloma, the FDA said.

The new drug is sanctioned for people who have received at least two prior standard therapies. It's approved to be given in combination with two other drugs, bortezomib and dexamethasone.

In November, an FDA advisory committee recommended against approving Farydak for people with relapsing multiple myeloma, saying its benefits did not outweigh its risks. But the drug's maker, Novartis, subsequently submitted additional information supporting the drug's use for people with multiple myeloma who had received at least two prior standard therapies, the FDA said.

The safety and effectiveness of Farydak in combination with bortezomib and dexamethasone were evaluated in clinical studies involving 193 people with . People who received the three-drug combination saw a delay in disease progression of about 10.6 months, compared with 5.8 months among people who received the other two drugs alone.

Farydak's label includes a boxed warning of the potential for fatal or severe heart problems, and severe diarrhea, the FDA said.

More common and less severe reactions could include diarrhea, fatigue, nausea, swelling of the extremities, loss of appetite, fever, vomiting and weakness.

Novartis is based in East Hanover, N.J.


Explore further

Pomalyst approved for advanced multiple myeloma

More information: The FDA has more about this approval.

Copyright © 2015 HealthDay. All rights reserved.

Citation: Farydak approved for multiple myeloma (2015, February 24) retrieved 23 February 2020 from https://medicalxpress.com/news/2015-02-farydak-multiple-myeloma.html
This document is subject to copyright. Apart from any fair dealing for the purpose of private study or research, no part may be reproduced without the written permission. The content is provided for information purposes only.
2 shares

Feedback to editors

User comments